CONCLUSION
Editorial assistance for this manuscript was provided by Erin
Falconer PhD of The Lockwood Group. Funding for editorial assistance
was provided by Valeant Dermatology, a subsidiary of
Valeant Pharmaceuticals North America LLC, Bridgewater, NJ.
H.E. Baldwin MD has participated on an advisory board for
Galderma and as a speaker for Allergan, Galderma, Medicis,
Onset Dermatologics, and Valeant. M. Nighland BS is an employee
and stockholder of Johnson & Johnson. C. Kendall MA
and D.A. Mays PharmD MBA are employees of Johnson &
Johnson Group of Consumer Companies, Inc. R. Grossman MD
is a Johnson & Johnson stockholder and employee of Valeant
Pharmaceuticals North America LLC. J. Newburger PhD was an
employee of Johnson & Johnson at the time of manuscript development
and is a current stockholder of Johnson & Johnson.
REFERENCES
- Haas AA, Arndt KA. Selected therapeutic applications of topical tretinoin. J Am Acad Dermatol. 1986;15(4 Pt 2):870-877.
- Stüttgen G. Historical perspectives of tretinoin. J Am Acad Dermatol. 1986;15(4 Pt 2):735-740.
- Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469-476.
- Kligman AM. The treatment of acne with topical retinoids: one man’s opinions. J Am Acad Dermatol. 1997;36(6 Pt 2):S92-S95.
- US Food and Drug Administration. Drugs@FDA: FDA-approved drug products. [Retin-A 1971]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed December 6, 2012.
- Thorne EG. Topical tretinoin research: an historical perspective. J Int Med Res. 1990;18(Suppl 3):18C-25C.
- US Food and Drug Administration. Drugs@FDA: FDA-approved drug products. [Renova 1995]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed December 6, 2012.
- Webster GF, Rawlings AV, eds. Acne and Its Therapy. New York, NY: Informa Healthcare USA, Inc. 2007.
- Retin-A Micro Pump (tretinoin gel) 0.04%/0.1% [package insert]. Los Angeles, CA: Ortho Dermatologics, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2010.
- Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41-47.
- Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids.Curr Pharm Des. 2000;6(9):919-931.
- Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379(6563):335-339.
- Francz PI, Conrad J, Biesalski HK. Modulation of UVA-induced lipid peroxidation and suppression of UVB-induced ornithine decarboxylase response by all-trans-retinoic acid in human skin fibroblasts in vitro. Biol Chem. 1998;379(10):1263-1269.
- Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993;129(4):415-421.
- Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol. 2005;6(4):245-253.
- Bhawan J, Gonzalez-Serva A, Nehal K, et al. Effects of tretinoin on photodamaged skin. A histologic study. Arch Dermatol. 1991;127(5):666-672.
- Ebanks JP, Wickett RR, Boissy RE. Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. Int J Mol Sci. 2009;10(9):4066-4087.
- Eichner R, Kahn M, Capetola RJ, Gendimenico GJ, Mezick JA. Effects of topical retinoids on cytoskeletal proteins: implications for retinoid effects on epidermal differentiation. J Invest Dermatol. 1992;98(2):154-161.
- Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical retinoids. Their uses in dermatology. Dermatol Clin. 1993;11(1):107-115.
- Houle B, Rochette-Egly C, Bradley WE. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells.Proc Natl Acad U S A. 1993;90(3):985-989.
- Li M, Song S, Lippman SM, et al. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene. 2002;21(3):411-418.
- Lotan R. Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res. 1994;54(7 Suppl):S1987-S1990.
- Bérard J, Laboune F, Mukuna M, Massé S, Kothary R, Bradley WE. Lung tumors in mice expressing an antisense RARβ2 transgene. FASEB J. 1996;10(9):1091-1097.
- Treuting PM, Chen LI, Buetow BS, et al. Retinoic acid receptor β2 inhibition of metastasis in mouse mammary gland xenografts. Breast Cancer Res Treat. 2002;72(1):79-88.
- Xu XC. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 2007;253(1):14-24.
- Webster GF. Evidence-based review: fixed-combination therapy and topical retinoids in the treatment of acne. J Drugs Dermatol. 2011;10(6):636-644.
- Biro DE, Shalita AR. Clinical aspects of topical retinoids. Skin Pharmacol. 1993;6(Suppl 1):53-60.
- Abramovits W, Oquendo M, Gupta AK. Veltin gel (clindamycin phosphate 1.2% and tretinoin 0.025%). Skinmed. 2011;9(1):49-51.
- Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-381.
- Eichenfield LF, Nighland M, Rossi AB, et al. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7(12):1129-1136.
- Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther. 1992;14(6):773-780.
- Schmidt N, Gans EH. Clindamycin 1.2% tretinoin 0.025% gel versus clindamycin gel treatment in acne patients: a focus on Fitzpatrick skin types. J Clin Aesthet Dermatol. 2011;4(6):31-40.
- Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(Suppl 1):S1-S37.